Biogen is abandoning its lackluster Alzheimers disease drug, Aduhelm.
The trouble is that Aduhelmnever really seemed to workas intended.
But other experts didnt buy what Biogen was selling.
The homepage of Aduhelm, soon after the drug won accelerated approval from the FDA in June 2021.Image: Tada Images (Shutterstock)
The company raised further eyebrows when it announced that the drugs list price would be $56,000 a year.
This investigationeventually foundthat the FDAs approval process of Aduhelm was rife with irregularities.
Biogen will not only pull Aduhelm from the market but also terminate its remaining clinical clinical trials of it.
Biogen has seen more success with its second-generation anti-amyloid drug Leqembi.
And its possible that future similar treatments orother interventionsreally will lead to substantial improvements in Alzheimers care someday soon.
If so, then Aduhelm might just end up becoming a messy footnote in an otherwise hopeful story.
News from the future, delivered to your present.
Can a Drug Prevent Alzheimers Disease Decades Before It Happens?
Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer’s.
